First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00402-4
Affiliations:
20
Authors:
18
Go to article
Institutions Authors Share
Roche R&D Center (China) Ltd., China
2.500000
 0.14
Genentech, Inc., United States of America (USA)
2.500000
 0.14
Asan Medical Center (AMC), South Korea
1.000000
 0.06
Samsung Medical Center (SMC), South Korea
1.000000
 0.06
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
 0.06
National Taiwan University Hospital (NTUH), Taiwan
1.000000
 0.06
Roche Products Limited, United Kingdom (UK)
1.000000
 0.06
Tel Aviv Sourasky Medical Center, Israel
1.000000
 0.06
Taipei Veterans General Hospital (TPEVGH), Taiwan
1.000000
 0.06
UCLA Health, United States of America (USA)
1.000000
 0.06
Yonsei Cancer Hospital, South Korea
1.000000
 0.06
The Royal Marsden Hospital - London, The Royal Marsden NHS Foundation Trust, United Kingdom (UK)
1.000000
 0.06
Monash Medical Centre (MMC), Australia
1.000000
 0.06
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)
0.500000
 0.03
University of Glasgow, United Kingdom (UK)
0.500000
 0.03
Jiangsu Hansoh Pharmaceutical Group Co., Ltd., China
0.500000
 0.03
Gilead, United States of America (USA)
0.500000
 0.03
Interested in Oncology and Carcinogenesis?